Cabometyx (cabozantinib) offers efficacy benefits in combination with Bristol Myers Squibb’s Opdivo (nivolumab) versus sunitinib for patients with previously untreated advanced renal cell carcinoma, regardless of prior nephrectomy status, according to data from a post-hoc exploratory analysis of the phase III CheckMate -9ER pivotal trial.
Over the course of his first six months as NCI director, Anthony Letai has contended with federal budget turbulence, a record-setting government shutdown, and concerns about the flow of over research dollars.
